Trials / Unknown
UnknownNCT03418584
Application of hybridAPC in the Treatment of Barrett
Application of hybridAPC in the Treatment of Barrett: a Multicenter, Prospective Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of the new technique of HybridAPC in the treatment of Barrett.
Detailed description
After thermal ablation of Barrett's esophagus, stricture formation is reported in 5 to over 10% of patients. Submucosal fluid injection prior to ablation may lower the risk of stricture formation. The new technique of HybridAPC which combines submucosal injection with APC is considered to reduce the complication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | HybridAPC | HybridAPC is a device which combines submucosal fluid injection with APC |
Timeline
- Start date
- 2017-12-05
- Primary completion
- 2020-12-05
- Completion
- 2021-12-05
- First posted
- 2018-02-01
- Last updated
- 2018-02-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03418584. Inclusion in this directory is not an endorsement.